Clover Health Reports Increased Net Loss and Negative Operating Cash Flow for 2025 Despite Revenue Growth
Summary
Clover Health's 2025 annual report shows a substantial increase in net loss and negative operating cash flow, alongside a worsening insurance benefits expense ratio, despite a 40.3% rise in total revenues.
Key Events
-
Full Year 2025 Financial Performance
Clover Health reported a net loss from continuing operations of $85.5 million for 2025, an 84.9% increase from $46.3 million in 2024. Total revenues grew by 40.3% to $1,924.3 million, but net medical claims incurred increased by 55.9% to $1,568.4 million. Adjusted EBITDA decreased significantly to $21.7 million in 2025 from $70.1 million in 2024.
-
Worsening Profitability Metrics
The Insurance Benefits Expense Ratio (BER) worsened to 90.9% in 2025 from 81.2% in 2024, indicating higher medical costs relative to premiums. Normalized Insurance BER also increased to 91.5% from 84.2%.
-
Shift to Negative Operating Cash Flow
The company's net cash flow from operating activities from continuing operations turned negative, with a use of $66.9 million in 2025, compared to a positive $82.5 million provided in 2024.
-
Share Repurchase Program Completed
The $20.0 million share repurchase program, authorized in May 2024, was fully exhausted in the first quarter of 2025, with $18.3 million repurchased in 2025 and $1.8 million in 2024.
Analysis
This annual report provides the full audited financial results for 2025, revealing a significant increase in net loss and a shift to negative operating cash flow, despite strong revenue growth. While the company achieved positive Adjusted EBITDA, it was substantially lower than the prior year, and the Insurance Benefits Expense Ratio worsened. Investors should note the deteriorating profitability metrics and cash burn from operations, which present a more challenging financial picture than suggested by earlier summary disclosures. The company's statement on sufficient liquidity for the next 12 months is a near-term positive, but the accumulated deficit and the need for potential future financing remain key considerations.
At the time of this filing, CLOV was trading at $2.09 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.94 to $4.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.